Continuous flow left ventricular assist devices: A valid option for heart failure patients

Swiss Medical Weekly

Volumn 142, Issue , 2012, Pages

  Carrel, Thierry ^a   Englberger, Lars ^a   Martinelli, Michele V ^a   Takala, Jukka ^b   Boesch, Claudia ^a   Sigurdardottir, Vilborg ^a   Gygax, Erich ^a   Kadner, Alexander ^a   Mohacsi, Paul ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Assist devices; Cardiac transplantation; Continuous flow devices; Destination therapy; Heart failure

Indexed keywords

BLOOD FLOW; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MORTALITY; PATIENT SELECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; TREATMENT INDICATION; VON WILLEBRAND DISEASE; COMORBIDITY; EQUIPMENT; EXTRACORPOREAL OXYGENATION; HEART ASSIST DEVICE; HEMODYNAMICS; HOSPITAL ADMISSION; METHODOLOGY;

COMORBIDITY; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; PERIOPERATIVE CARE; WAITING LISTS;

EID: 84870458180     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13701     Document Type: Review

References (45)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;1:30-41.
2. Mohacsi P, Moschovitis G, Tanner H, Hess OM, Hullin R. Prevalence, increase and costs of heart failure. Heart and Metabolism. 2001;14:9-16.
3. Lietz K, Miller LW. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005. J Am Coll Cardiol. 2007;50:1282-90. (Pubitemid 47405140)
4. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplantation report-2010. J Heart Lung Transplant. 2010;10:1089-103.
5. Rose EA, Gelijns AC, Moskowitz AJ, Group RS. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345;1435-43.
6. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN 3rd. Chronic mechanical circulatory support for intrope-depenent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741-7. (Pubitemid 47239315)
7. Jeevanandam V. The evolution of cardiac assist device technology. J Heart Lung Transplant. 2011;29:11-2.
8. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115-23.
9. Lietz K, Miller LW. Patient selection for left-ventricular assist device. Curr Opin Cardiol. 2009;24:246-51.
10. Lietz K. Destination therapy: patient selection and current outcomes. J Card Surg. 2010;25:462-71.
11. Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart failure patients. Eur J Cardiothorac Surg. 2010;37:357-61.
12. Slaughter MS, Bostic R, Tong K, Russo M, Rogers JG. Temporal changes in hospital costs for left ventricular assist device implantation. J Card Surg. 2011;26:535-41.
13. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-51.
14. Strueber M, O'Driscoll G, Khaghani A, Levy WC, Wieselthaler GM, Investigators H. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol. 2011;57:1375-82.
15. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MS, Milano CA, et al. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998-2005. Circ Heart Fail. 2009;2:3-10.
16. Froesch P, Martinelli M, Meier P, Cook S, Hullin R, Windecker S, et al. Clinical use of temporary percutaneous left ventricular assist devices. Catheter Cardiovasc Interv. 2011;78:304-11.
17. Dandel M, Weng Y, Siniawski H, Stepanenko A, Krabatsch T, Potapov E, et al. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J. 2011;32:1148-60.
18. Krabatsch T, Schweiger M, Dandel M, Stepanenko A, Drews T, Potapov E, et al. Is bridge to recovery more likely with pulsatile left ventricular assist devices than with nonpulsatile flow systems? Ann Thorac Surg. 2011;91:1335-40.
19. Naiyanetr P, Moscato F, Vollkron M, Zimpfer D, Wiesenthaler G, Schirma H. Continuous assessment of cardiac function during rotary blood pump support: a contractility index derived from pump flow. J Heart Lung Transplant. 2011;29:37-44.
20. Beyersdorf F, Schlensak C, Berchtold-Herz M, Trummer G. Regression of "fixed" pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices. J Thorac Cardiovasc Surg. 2010;140:747-9.
21. Cleveland JC Jr, Grover FL, Fullerton DA, Campbell DN, Mitchell MB, Lindenfeld J, et al. Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. J Thorac Cardiovasc Surg. 2008;136:774-7.
22. Patlolla V, Patten RD, Denofrio D, Konstam MA, Krishnamani R. The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry. J Am Coll Cardiol. 2009;53:264-71.
23. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller LW, Kormos RL, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28:535-41.
24. Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant. 2009;28:827-33.
25. Klotz S, Valhaus C, Riehl C, Reitz C, Sindermann JR, Scheld HH. Preoperative prediction of post-VAD implant mortality using easily accessible clinical parameters. J Heart Lung Transplant. 2011;29:45-52.
26. Williams ML, Trivedi JR, McCants KC, Prabhu SD, Birks EJ, Oliver L, Slaughter MS. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. Ann Thorac Surg. 2011;91:1330-3.
27. Rogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al.; HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826-34.
28. Osorio J. Device therapy: continuous flow LVAD improves quality of life. Nature Review Cardiology. 2010;7:360.
29. Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012 Jun 1. [Epub ahead of print]
30. Krishan K, Nair A, Pinney S, Adams D, Anyanwu AC. Low incidence of bleeding-related morbidity with left ventricular assist device implantation in the current era. Artif Organs. 2012;36:746-51.
31. Felix SE, Martina JR, Kirkels JH, Klöpping C, Nathoe H, Sukkel E, et al. Continuous-flow left ventricular assist device support in patients with advanced heart failure: points of interest for the daily management. Eur J Heart Fail. 2012;14:351-6.
32. Kurien S, Hughes KA. Anticoagulation and bleeding in patients with ventricular assist devices: walking the tightrope. AACN Adv Crit Care. 2012;23:91-8.
33. Califano S, Pagani FD, Malani PN. Left ventricular assist device-associated infections. Infect Dis Clin North Am. 2012;26:77-87.
34. Boyle A. Arrhythmias in patients with ventricular assist devices. Curr Opin Cardiol. 2012;27:13-8.
35. Mangi AA. Right ventricular dysfunction in patients undergoing left ventricular assist device implantation: predictors, management, and device utilization. Cardiol Clin. 2011;29:629-37.
36. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score. A pre-operative tool for assessing the risk of right ventricualr failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163-72. (Pubitemid 351713685)
37. Crow S, Ranjit J, Boyle A, Shumway S, Liao K, Colvin-Adams M, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208-15.
38. Uriel N, Pak S-W, Jorde UP, Jude B, Susen S, Vincentelli A, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207-13.
39. Slaughter M. Hematologic effects of continuous flow left ventricular assist devices. J Cardiovasc Transl Res. 2010;3:618-24.
40. Crow S, Chen D, Milano C, Thomas W, Joyce L, Placentino Vr, et al. Acquired von-Willebrandt syndrome in continuous flow ventricular assist device recipients. Ann Thorac Surg. 2010;90:1263-9.
41. Slaughter MS. Long-term continuous flow left ventricular assist device support and end organ function: prospects for destination therapy. J Cardiac Surg. 2010;25:490-4.
42. Mishra V, Geiran O, Fiane AE, Sørensen G, Andresen S, Olsen E, et al. Costs and reimbursement gaps after implementation of third-generation left ventricular assist devices. J Heart Lung Transplant. 2011;29:72-8.
43. Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost effectiveness analysis of continuous flow left ventricular assist devices as destination therapy. Circ Heart Fail 2011, Epub ahead of print.
44. Lahpor JR. State of the art: implantable ventricular assist devices. Curr Opin Organ Transplant. 2009;14:554-9.
45. Potapov E, Krabatsch T, Ventura HO, Hetzer R. Advances in mechanical circulatory support: year in review. J Heart Lung Transplant. 2011;30:487-93.